Likewise, the AKT inhibitor drug AZD5363 in patients with AKT1 E17K-mutant ER+ breast cancer and MK-2206 in patients with PIK3CA-mutant ER+ and HER2– breast cancer was investigated in neoadjuvant settings for individualized treatment options. Here, ERBB2 is linked to breast cancer.